SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2008 Biotech Stock Picking for Charity -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (132)2/14/2008 10:00:40 AM
From: rkrw  Read Replies (1) | Respond to of 322
 
There's certainly a lot of collusion between generics and brands. Then you have cases like teva launching at risk on Protonix. From what I understand, Wyeth strongly thinks their patents are valid and hopes to go after Teva for treble damages. They want to make an example out of teva and show other generic companies they can't be walked on. That case is going to be fun to watch, treble damages could be massive.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News